Comparing the efficacy of oral misoprostol vs dinoprostone gel in labor
Phase 4
- Conditions
- Health Condition 1: O80- Encounter for full-term uncomplicated deliveryHealth Condition 2: O00-O9A- Pregnancy, childbirth and the puerperium
- Registration Number
- CTRI/2024/05/067927
- Lead Sponsor
- Dr Suvetha Shree
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Post dated pregnancy, singleton pregnancy, vertex presentation, other indications of induction like GDM,GHTN,FGR
Exclusion Criteria
Multiple gestation, preterm, non vertex presentation, previous LSCS, cephalopelvic disproportion
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms differentiate oral misoprostol from intracervical dinoprostone gel in labor induction?
How does CTRI/2024/05/067927 compare oral misoprostol and dinoprostone gel efficacy to standard-of-care oxytocin protocols?
Which biomarkers predict successful cervical ripening with misoprostol versus dinoprostone in O80/O00-O9A pregnancies?
What adverse event profiles distinguish misoprostol from dinoprostone gel in labor induction for MTAP-related uterine conditions?
Are there synergistic combination therapies involving misoprostol or dinoprostone for managing RAS pathway dysregulation in obstetric care?